<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00482638</url>
  </required_header>
  <id_info>
    <org_study_id>0493-008</org_study_id>
    <secondary_id>2007_571</secondary_id>
    <nct_id>NCT00482638</nct_id>
  </id_info>
  <brief_title>Study of Safety, Tolerability and Efficacy of MK0493 in Obese Patients (0493-008)(COMPLETED)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      To assess the effect of MK0493 on body weight, blood pressure, mood, and appetite.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 12, 2004</start_date>
  <completion_date type="Actual">October 29, 2004</completion_date>
  <primary_completion_date type="Actual">October 29, 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Obesity</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK0493</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is between 21 and 65 years

          -  Patient is able to read and understand and complete study questionnaires

          -  Patient is not pregnant or breast-feeding and does not plan to become pregnant for the
             duration of the study and post-study follow-up period

        Exclusion Criteria:

          -  Patient has a history of significant psychiatric disorder (such as major depression,
             bipolar disorder, bulimia, or anorexia nervosa

          -  Patient is HIV positive as determined by medical history

          -  Patient has undergone surgical treatment for obesity

          -  Patient plans to consume more than two 8 ounce glasses of grapefruit juice per day
             during the study

          -  Patient participated in another clinical study involving an investigational drug)
             within 3 months prior to Visit 1

          -  Patient is currently a heavy consumer of alcohol (&gt;2 drinks per day or &gt;14 drinks per
             week [1 drink is defined as 2 oz hard alcohol, 5 oz wine, 12 oz beer], or uses
             (including recreational use) any illicit drugs, or has a history of drug or alcohol
             abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <results_reference>
    <citation>Krishna R, Gumbiner B, Stevens C, Musser B, Mallick M, Suryawanshi S, Maganti L, Zhu H, Han TH, Scherer L, Simpson B, Cosgrove D, Gottesdiener K, Amatruda J, Rolls BJ, Blundell J, Bray GA, Fujioka K, Heymsfield SB, Wagner JA, Herman GA. Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacy. Clin Pharmacol Ther. 2009 Dec;86(6):659-66. doi: 10.1038/clpt.2009.167. Epub 2009 Sep 9.</citation>
    <PMID>19741604</PMID>
  </results_reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>June 1, 2007</study_first_submitted>
  <study_first_submitted_qc>June 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2007</study_first_posted>
  <last_update_submitted>November 13, 2019</last_update_submitted>
  <last_update_submitted_qc>November 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

